Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Nov 13, 2020

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

Nov 10, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results

Nov 04, 2020

Fulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 03, 2020

Fulcrum Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, November 10, 2020 at 8:00 a.m. ET

Oct 05, 2020

Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease

Oct 01, 2020

Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society

Sep 25, 2020

Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting

Sep 08, 2020

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

Aug 11, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

Aug 11, 2020

Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 30

Investor Tools

Privacy Policy
EU Privacy Policy
Terms of Use

Twitter
LinkedIn
Instagram

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact